Phillip G. Febbo, Chief Scientific Officer and Chief Medical Officer at Veracyte, shared Conquer Cancer’s post on LinkedIn, adding:
“Honored to be invited to join the Conquer Cancer board – As a previous recipient of an ASCO Young Investigator Award (no, I am not sharing the year…), I know how important the activities of the Conquer Cancer Foundation are to support early career and oncology research! Excited to help and, fair warning for my colleagues in Industry, I am looking forward to the opportunity to connect about how we can collectively lean in during these challenging times to support the Conquer Cancer Foundation, early career development, and cancer research!”
Quoting Conquer Cancer on LinkedIn:
“We are honored to welcome Phillip G. Febbo, MD, to the Conquer Cancer Board of Directors!
Dr. Febbo joins us with an extensive background in both academia and industry, currently serving as the Chief Scientific and Medical Officer at Veracyte, Inc. His distinguished career includes leadership roles at Illumina and Genomic Health, as well as over 15 years in academia at institutions such as UCSF and Dana-Farber.
Throughout his career, Dr. Febbo has remained dedicated to improving outcomes for people with cancer by driving the availability of high-quality molecular diagnostics and utilizing genomics to understand the biology of the disease. With a deep background in translational research and a focus on transformative care, he has quickly become a vital contributor to our mission.
Please join us in welcoming Dr. Febbo to the team as we work together to conquer cancer!”
Other articles featuring Conquer Cancer on OncoDaily.